Mestinon
Formulated to address muscle weakness, utilized to support neuromuscular transmission and to relieve fatigue in myasthenia gravis.
Strengths: 60mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Acetylcholinesterase Inhibitor
- Pharmacological class
Parasympathomimetic
- Contraindications
mechanical intestinal obstruction; urinary tract obstruction; hypersensitivity
- Minor side effects
nausea; abdominal cramps; diarrhoea
- Moderate side effects
bradycardia; bronchial secretions; muscle fasciculations
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Meda
- Onset Time
30–60 minutes
- Duration
4–6 hours
- Storage instructions
Store at room temperature in a dry place.
- Drug interactions
beta-blockers; aminoglycosides
- Age restrictions
Suitable for children and adults under specialist guidance.
Precautions and warnings
caution in patients with asthma; monitor for cholinergic crisis; use with care in patients with bradycardia
Serious side effects
cholinergic crisis — requires immediate medical attention; convulsions — requires immediate medical attention
Patient summary
Formulated to address muscle weakness, utilized to support neuromuscular transmission and to relieve fatigue in myasthenia gravis.
Mechanism of action
Pyridostigmine inhibits the enzyme acetylcholinesterase, which breaks down acetylcholine at the neuromuscular junction, thereby increasing the availability of acetylcholine to stimulate muscle contraction.
Pregnancy and breastfeeding
Pregnancy: Use only when strictly necessary. Breastfeeding: Small amounts excreted; monitor infant.
Mestinon
Formulated to address muscle weakness, utilized to support neuromuscular transmission and to relieve fatigue in myasthenia gravis.
Editorial Notes
- Active ingredient(s): Pyridostigmine
- Listed indication(s): Myasthenia Gravis
Available option
- 60 tablets - 60 mg573-60-mg-1280